Skip to main content

Advertisement

SpringerLink
Log in

Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effect of topical prophylaxis with brinzolamide–brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF).

Methods

This prospective comparative study included 56 eyes of 47 patients treated with intravitreal injections of anti-VEGF, and they were randomly divided into two groups. In control group (25 eyes), no prophylactic medication was used, whereas in case group (31 eyes) one drop of a fixed combination of brinzolamide–brimonidine was instilled two hours before the injection. IOP was measured before the injection and at 1 min, 10 min and 30 min post-injection in all eyes.

Results

The mean IOP before injection at 1 min, 10 min and 30 min post-injection was 16,6 ± 2,8 mmHg, 53,4 ± 12 mmHg, 26,4 ± 5,5 mmHg and 17,9 ± 4 mmHg, respectively, in control group and 15,1 ± 3,4 mmHg, 42,6 ± 8,4 mmHg, 21,4 ± 5,5 mmHg and 12,4 ± 3,5 mmHg, respectively, in case group. At 1 min, 10 min and 30 min post-injection, the mean IOP was significantly lower in case group compared with control group (p < 0,001, p = 0,0014 and p < 0,0001, respectively), but no difference at the pre-injection IOP between the two groups was found (p = 0,09).

Conclusions

The prophylactic administration of one drop of brinzolamide–brimonidine fixed combination significantly reduces the IOP spikes during the first 30 min after the intravitreal anti-VEGF injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data can be shared upon request.

References

  1. Bandello F, De Benedetto U, Knutsson KA et al (2011) Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 5:1303–1308

    Article  CAS  Google Scholar 

  2. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  CAS  Google Scholar 

  3. Arias L, Planas N, Prades S et al (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92:1035–1039

    Article  CAS  Google Scholar 

  4. Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149

    Article  Google Scholar 

  5. Bakri SJ, Pulido JS, McCannel CA et al (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 23:181–185

    Article  CAS  Google Scholar 

  6. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  CAS  Google Scholar 

  7. Murray CD, Wood D, Allgar V et al (2014) Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond) 28:1218–1222

    Article  CAS  Google Scholar 

  8. Hoguet A, Chen PP, Junk AK et al (2019) The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of ophthalmology. Ophthalmology 126:611–622

    Article  Google Scholar 

  9. Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597

    Article  Google Scholar 

  10. Eadie BD, Etminan M, Carleton BC et al (2017) Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 135:363–368

    Article  Google Scholar 

  11. Skalicky SE, Ho I, Agar A et al (2012) Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 43:328–334

    Article  Google Scholar 

  12. Bracha P, Moore NA, Ciulla TA et al (2018) The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 63:281–295

    Article  Google Scholar 

  13. El Chehab H, Le Corre A, Giraud JM et al (2012) Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections. J Fr Ophtalmol 35:614–621

    Article  Google Scholar 

  14. Felfeli T, Hostovsky A, Trussart R et al (2019) Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol 103:1388–1394

    Article  Google Scholar 

  15. Katayama BY, Bonini-Filho MA, Messias AM et al (2014) Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma 23:461–463

    Article  Google Scholar 

  16. Theoulakis PE, Lepidas J, Petropoulos IK et al (2010) Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 227:280–284

    Article  CAS  Google Scholar 

  17. Aung T, Laganovska G, Hernandez Paredes TJ et al (2014) Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 121:2348–2355

    Article  Google Scholar 

  18. Sharma S, Trikha S, Perera SA et al (2015) Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol 9:2201–2207

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Hollands H, Wong J, Bruen R et al (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42:807–811

    Article  Google Scholar 

  20. Kim JE, Mantravadi AV, Hur EY et al (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930–934

    Article  CAS  Google Scholar 

  21. Mojica G, Hariprasad SM, Jager RD et al (2008) Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 92:584

    Article  CAS  Google Scholar 

  22. Shoeibi N, Ghosi Z, Jafari H et al (2021) Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections. Int Ophthalmol 41:1081–1090

    Article  Google Scholar 

  23. Frenkel MP, Haji SA, Frenkel RE (2010) Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 128:1523–1527

    Article  Google Scholar 

  24. Carnota-Mendez P, Mendez-Vazquez C, Otero-Villar J et al (2014) Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol 24:771–777

    Article  Google Scholar 

  25. Cvetkovic RS, Perry CM (2003) Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20:919–947

    Article  CAS  Google Scholar 

  26. Adkins JC, Balfour JA (1998) Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 12:225–241

    Article  CAS  Google Scholar 

  27. Han JA, Frishman WH, Wu Sun S et al (2008) Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 16:95–108

    Article  Google Scholar 

  28. Kaiserman I, Fendyur A, Vinker S (2009) Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 34:517–522

    Article  CAS  Google Scholar 

  29. van der Valk R, Webers CA, Schouten JS et al (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112:1177–1185

    Article  Google Scholar 

  30. Pece A, Allegrini D, Montesano G et al (2016) Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clin Ophthalmol 10:1131–1138

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218

    Article  CAS  Google Scholar 

Download references

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, “Elpis” General Hospital of Athens, 7 Dimitsanas Street, 115 22, Athens, Greece

    Maria Dettoraki, Eleni Rapti, Dimitrios Fragkos, Ioannis Theiopoulos, Anthi Legaki, Alexandra Gkounta, Despina Anyfantaki & Frini Riga

Authors
  1. Maria Dettoraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleni Rapti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios Fragkos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ioannis Theiopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anthi Legaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandra Gkounta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Despina Anyfantaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Frini Riga
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Maria Dettoraki, Eleni Rapti and Dimitrios Fragkos. The first draft of the manuscript was written by Maria Dettoraki and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Maria Dettoraki.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Informed consent for publication of their data and photographs was obtained from the patients.

Ethical approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained from the Ethics Committee of “Elpis” General Hospital, Athens, Greece (approval number 1992).

Clinical trials registration

ClinicalTrials.gov Identifier: NCT04523844, August 24, 2020, retrospectively registered.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dettoraki, M., Rapti, E., Fragkos, D. et al. Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. Int Ophthalmol 41, 3191–3198 (2021). https://doi.org/10.1007/s10792-021-01885-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-021-01885-z

Keywords

Search

Navigation